UHCs typical prior authorization requirements for Wegovy and Zepbound include: BMI documentation A documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea Comorbidity evidence Clinical records documenting the specific comorbidities that support the medical necessity of treatment Supervised weight management history Evidence of participation in a structured weight management program, which may include diet, exercise, and behavioral counseling, typically for 3 to 6 months prior to the request Prescriber qualifications The prescriber must be a physician, nurse practitioner, or physician assistant with appropriate prescribing authority UHC reviews prior authorizations against specific clinical policy bulletins

In general, Finland researchers think that BPC-157 promotes healing, lowers inflammation, and supports general tissue health and well-being by combining angiogenic, anti-inflammatory, and antioxidant mechanisms
Restarting the treatment without consulting a healthcare provider could also trigger serious gastrointestinal side effects
2024 Biopreventative Company Inc